Developer docs
API playgroundTry for free, no card

Search company profiles

VKT Pharma

Full company profile

uuid003p541

Namestring
VKT Pharma
Legal namestring
VKT Pharma Private Limited
Websiteurl
vktpharma.com
Company typeenum
Private
Founded yearint
2009
Descriptiontext

VKT Pharma Private Limited is an India-based pharmaceutical contract manufacturer and CRAMS (Contract Research and Manufacturing Services) provider founded in 2009 and headquartered in Hyderabad, Telangana. The company specializes in solid oral dosage forms—tablets, capsules, and ready-to-fill immediate or modified-release pellets—serving major generic and brand pharmaceutical companies across 10+ countries. Manufacturing is concentrated at a 16,320 sq.mt. facility in Srikakulam District, Andhra Pradesh, with five dedicated blocks covering OSD production (4.4 billion tablet/capsule nameplate capacity across three phases, of which 1.5 billion is currently operational), pellet manufacturing (360 MT/annum across two modules), central warehousing, administration, and engineering/utilities. VKT Pharma maintains cGMP accreditations from the Indian FDA (2015), WHO GMP (2016 and 2017), the US FDA (June 2018), and the EU GMP (July 2018), enabling supply into regulated generics markets globally. The 25,000 sq.ft in-house R&D center covers formulation development, analytical development, and a pilot plant.

The product portfolio spans commercial pellets (Omeprazole 8.5%/9.0%, Itraconazole 20%/22%/32.25%, Esomeprazole 8.5%, Duloxetine 17%), finished formulations (Ranitidine 150/300 mg, Levetiracetam 250–1000 mg, Tadalafil 2.5–20 mg), and an active development pipeline that includes anti-retroviral tablets and capsules (Darunavir, Tenofovir/Emtricitabine, Atazanavir/Ritonavir, Lopinavir/Ritonavir), higher-strength and MUPS-based pellets, gastro-retentive systems, and bi-layered tablets. Technological capabilities include Para IV first-to-file products with 180-day exclusivity, modified-release formulations (delayed, extended, sustained release), colon-specific pellet targeting, bioequivalence/IVIVC development, and taste-masking. Revenue is generated through three streams: CRAMS (end-to-end formulation to commercial manufacturing), product-specific development and manufacturing partnerships with deal structures ranging from free-for-service to profit-sharing, and the sale of finished solid dosage form products. Pricing is not publicly disclosed and is negotiated on a project-by-project basis.

VKT Pharma operates as an associate company of SMS Pharmaceuticals Ltd, with P. Ramesh Babu serving as Chairman & Managing Director of both entities and P. Vamsi Krishna as Director. The company employs 251–500 people and follows a B2B sales-led go-to-market, reaching customers through strategic partnerships, joint ventures, and alliances with "highly reputed Pharma majors." In November 2025, VKT Pharma received US FDA approval for its reformulated Ranitidine tablets, marking the drug's return to the US market after a five-year absence due to NDMA impurity concerns—an event that drove an 18% share price increase in parent SMS Pharmaceuticals. The company has not disclosed any private equity or venture capital ownership.

Short descriptiontext

VKT Pharma is an India-based pharmaceutical contract manufacturer of tablets, capsules, and pellets (solid oral dosage forms), serving global generic and brand pharmaceutical companies through CRAMS partnerships across 10+ countries with US FDA, EU GMP, and WHO GMP accreditations.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersHyderabad, India
HQ citystring
Hyderabad
HQ countrystring
India
HQ regionstring
Asia
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
generic pharmaceutical manufacturing, contract research manufacturing services, solid dosage form manufacturing, pharmaceutical pellets production, novel drug delivery systems
Industry2 codes
PRIMARYHLAIABAH
Generic Finished Dosage Form (FDF) Manufacturing
SECONDARYHLAGAHAL
GMP Scale-Up, Tech Transfer & Process Validation (PPQ)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services
NAICS code2 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Pharmaceutical and Medicine Manufacturing32541
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Pharmaceutical Contract Manufacturing
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1Contract Research and Manufacturing Services (CRAMS)
TypeProfessional Services
Description

VKT Pharma offers Contract Research and Manufacturing Services (CRAMS) providing pharmaceutical companies with end-to-end solutions from product development to delivery. Services include formulation development, analytical development, regulatory affairs, and commercial manufacturing.

vktpharma.com
2Generic Product Development and Manufacturing Partnerships
TypeLicensing Royalties
Description

Customized deal structures ranging from Free-For-Service to Profit Sharing collaborations for Generic Product development and manufacturing partnerships. Focus on Therapeutically Equivalent ANDA-based products, OTC and other products on a case-by-case basis.

vktpharma.com
3Finished Solid Dosage Form Products
TypeOne Time License
Description

Manufacturing and sale of finished solid dosage forms including Tablets (Ranitidine, Levetiracetam, Tadalafil), Capsules, and Pellets (Omeprazole, Itraconazole, Esomeprazole, Duloxetine) across various therapeutic segments.

vktpharma.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Supply Chain, Operations, Technology or R&D, Personnel, Infrastructure, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

VKT Pharma is a vertically integrated pharmaceutical company that manufactures and supplies tablets, capsules, and ready-to-fill immediate or modified-release pellets for generic drug formulations. The company offers Contract Research and Manufacturing Services (CRAMS), Novel Drug Delivery Systems (NDDS), and end-to-end pharmaceutical solutions spanning product development, formulation development, analytical development, regulatory affairs, and commercial manufacturing across a wide range of therapeutic segments including anti-ulcer, anti-fungal, anti-depressant, anti-retroviral, anti-epileptic, and BPH treatments.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • First-to-file status and 180 days exclusivity achieved for number of Para IV products
+1 more record
Product overview1 text field

VKT Pharma is a quality-driven pharmaceutical company with vertically integrated operations spanning the entire pharmaceutical value chain from product development to delivery. The company specializes in Research & Development, Manufacturing and Marketing of Solid Dosage Forms with focus on Tablets, Capsules & Ready to Fill Immediate or Modified release Pellets. The core product portfolio includes Commercial Pellets (Omeprazole, Itraconazole, Esomeprazole, Duloxetine), Finished Formulations (Ranitidine Tablets, Levetiracetam Tablets, Tadalafil Tablets), and an extensive development pipeline including anti-retroviral products. The company offers Contract Research and Manufacturing Services (CRAMS) and Novel Drug Delivery Systems (NDDS) alongside formulation development services. Manufacturing operations are conducted across dedicated blocks: Block A (OSD - 4.4Bn tablets/capsules capacity), Block B (Pellets - 360 MT/annum capacity), and Block C (Central Warehouse).

Product and service6 records
1Commercial Pellets (Omeprazole, Itraconazole, Esomeprazole, Duloxetine)
CategoryPharmaceutical Pellets
Description

Commercially available pharmaceutical pellets including Omeprazole Pellets (8.5% & 9.0%), Itraconazole Pellets (20%, 22% & 32.25%), Esomeprazole Pellets (8.5%), and Duloxetine Pellets (17%) for anti-ulcer, anti-fungal, and anti-depressant therapeutic segments.

2Ranitidine Tablets (150mg, 300mg)
CategoryFinished Formulations - Tablets
Description

Ranitidine Tablets in 150mg and 300mg strengths for anti-ulcer treatment, recently approved by US FDA after reformulation addressing NDMA impurity concerns.

3Levetiracetam Tablets (250mg, 500mg, 750mg, 1000mg)
CategoryFinished Formulations - Tablets
Description

Levetiracetam Tablets in 250mg, 500mg, 750mg, and 1000mg strengths for anti-epileptic treatment.

4Tadalafil Tablets (2.5mg, 5mg, 10mg, 20mg)
CategoryFinished Formulations - Tablets
Description

Tadalafil Tablets in 2.5mg, 5mg, 10mg, and 20mg strengths for erectile dysfunction (ED) treatment.

5Formulation Development Services
CategoryR&D Services
Description

Comprehensive formulation development for tablets (immediate release, delayed release, extended release, sustained release, bi-layered, coated, MUPs, fixed dose combinations, gastro-retentive systems, sublingual), capsules, pellets, liquid orals, and powders/granules.

6Contract Research and Manufacturing Services (CRAMS)
CategoryContract Manufacturing Services
Description

End-to-end pharmaceutical solutions from research to delivery of finished products, including 505(b)(2) and new drug product development, platform technology analysis, and regulatory support.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeStrategic or Co-development Partner
Description

SMS Pharmaceuticals Ltd is the parent/associate company of VKT Pharma. VKT Pharma operates as an associate firm under the SMS Group. The relationship provides strategic alignment and shared resources within the Indian pharmaceutical industry. SMS Pharma's stock performance (18% gain following VKT's US FDA approval) demonstrates the strategic importance of this partnership.

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Indian pharmaceutical company with strong ARV franchise and formulation manufacturing capabilities; comparable through its presence in VKT's anti-retroviral development pipeline space and its generic solid-dosage manufacturing for global markets.

TypeEmerging player
Description

Indian CDMO with API, formulation, and CRO services targeting global pharma; comparable to VKT as a mid-sized Indian player pursuing regulated-market manufacturing and complex formulation services.

TypeDirect peer
Description

Indian pharmaceutical manufacturer focused on finished dosages, API, and intermediates with strong pellet and tablet capabilities serving global generic markets; highly comparable to VKT in product mix (tablets, capsules, pellets) and CRAMS-style services targeting regulated markets.

TypeDirect peer
Description

Indian pharmaceutical company specializing in complex generics and Para IV filings for the US market, with strong modified-release and oncology product development; closely comparable to VKT's complex-generics, Para IV, and first-to-file focus.

TypeBroad incumbent
Description

Indian API and intermediates manufacturer with growing formulation services and strong regulatory credentials; competes in the CDMO and complex generics space that VKT targets, particularly for global pharma partners.

TypeBroad incumbent
Description

Large Indian pharmaceutical company with substantial generic finished dosage, API, and ARV franchises plus US FDA-approved facilities; competes for similar CRAMS and generic formulation contracts although at a much larger scale.

TypeBroad incumbent
Description

Major Indian generics and CDMO player with US FDA-inspected facilities offering formulation development, contract manufacturing, and complex generics including modified-release products, overlapping VKT's target market.

TypeDirect peer
Description

Parent/associate company of VKT Pharma and a leading Indian API manufacturer with growing formulation interests; shares leadership, strategic alignment, and Hyderabad base, making it the most direct comparability benchmark for VKT's operations.

TypeBroad incumbent
Description

Global CDMO with development and manufacturing capabilities across sterile injectables, oral solids, and APIs; directly comparable in CRAMS service offering but operates at much larger scale across multiple geographies.

10ScieGen Pharmaceuticals
TypeDirect peer
Description

US-based but India-manufactured generic pharmaceuticals producer focused on solid oral dosage forms with US FDA-approved facilities; similarly positioned as a mid-tier CDMO/generic player competing for outsourced manufacturing partnerships and complex generic approvals.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature8 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance4 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

VKT Pharma

Pharmaceutical Contract Manufacturingvktpharma.com

VKT Pharma is an India-based pharmaceutical contract manufacturer of tablets, capsules, and pellets (solid oral dosage forms), serving global generic and brand pharmaceutical companies through CRAMS partnerships across 10+ countries with US FDA, EU GMP, and WHO GMP accreditations.

What VKT Pharma does

VKT Pharma Private Limited is an India-based pharmaceutical contract manufacturer and CRAMS (Contract Research and Manufacturing Services) provider founded in 2009 and headquartered in Hyderabad, Telangana. The company specializes in solid oral dosage forms—tablets, capsules, and ready-to-fill immediate or modified-release pellets—serving major generic and brand pharmaceutical companies across 10+ countries. Manufacturing is concentrated at a 16,320 sq.mt. facility in Srikakulam District, Andhra Pradesh, with five dedicated blocks covering OSD production (4.4 billion tablet/capsule nameplate capacity across three phases, of which 1.5 billion is currently operational), pellet manufacturing (360 MT/annum across two modules), central warehousing, administration, and engineering/utilities. VKT Pharma maintains cGMP accreditations from the Indian FDA (2015), WHO GMP (2016 and 2017), the US FDA (June 2018), and the EU GMP (July 2018), enabling supply into regulated generics markets globally. The 25,000 sq.ft in-house R&D center covers formulation development, analytical development, and a pilot plant.

The product portfolio spans commercial pellets (Omeprazole 8.5%/9.0%, Itraconazole 20%/22%/32.25%, Esomeprazole 8.5%, Duloxetine 17%), finished formulations (Ranitidine 150/300 mg, Levetiracetam 250–1000 mg, Tadalafil 2.5–20 mg), and an active development pipeline that includes anti-retroviral tablets and capsules (Darunavir, Tenofovir/Emtricitabine, Atazanavir/Ritonavir, Lopinavir/Ritonavir), higher-strength and MUPS-based pellets, gastro-retentive systems, and bi-layered tablets. Technological capabilities include Para IV first-to-file products with 180-day exclusivity, modified-release formulations (delayed, extended, sustained release), colon-specific pellet targeting, bioequivalence/IVIVC development, and taste-masking. Revenue is generated through three streams: CRAMS (end-to-end formulation to commercial manufacturing), product-specific development and manufacturing partnerships with deal structures ranging from free-for-service to profit-sharing, and the sale of finished solid dosage form products. Pricing is not publicly disclosed and is negotiated on a project-by-project basis.

VKT Pharma operates as an associate company of SMS Pharmaceuticals Ltd, with P. Ramesh Babu serving as Chairman & Managing Director of both entities and P. Vamsi Krishna as Director. The company employs 251–500 people and follows a B2B sales-led go-to-market, reaching customers through strategic partnerships, joint ventures, and alliances with "highly reputed Pharma majors." In November 2025, VKT Pharma received US FDA approval for its reformulated Ranitidine tablets, marking the drug's return to the US market after a five-year absence due to NDMA impurity concerns—an event that drove an 18% share price increase in parent SMS Pharmaceuticals. The company has not disclosed any private equity or venture capital ownership.

VKT Pharma firmographics

Firmographics
Name
VKT Pharma
Legal name
VKT Pharma Private Limited
Website
https://vktpharma.com
Company type
Private
Founded year
2009
Operating status
Operating
Headcount range
101–250 employees
Short description
VKT Pharma is an India-based pharmaceutical contract manufacturer of tablets, capsules, and pellets (solid oral dosage forms), serving global generic and brand pharmaceutical companies through CRAMS partnerships across 10+ countries with US FDA, EU GMP, and WHO GMP accreditations.
Ownership category
akta.pro rank

VKT Pharma industry classification

Industry
Product category
Pharmaceutical Contract Manufacturing
NAICS
Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (32541)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIABAH
Generic Finished Dosage Form (FDF) Manufacturing
SECONDARYHLAGAHAL
GMP Scale-Up, Tech Transfer & Process Validation (PPQ)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services

Keywords

  • Generic pharmaceutical manufacturing
  • Contract research manufacturing services
  • Solid dosage form manufacturing
  • Pharmaceutical pellets production
  • Novel drug delivery systems

Where VKT Pharma is headquartered

Location

Headquarters

HQ city
Hyderabad
HQ country
India
HQ region
Asia

Offices2 records

Markets served

VKT Pharma business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Supply Chain, Operations, Technology or R&D, Personnel, Infrastructure, Marketing or Sales

Revenue model

  1. Contract Research and Manufacturing Services (CRAMS): VKT Pharma offers Contract Research and Manufacturing Services (CRAMS) providing pharmaceutical companies with end-to-end solutions from product development to delivery. Services include formulation development, analytical development, regulatory affairs, and commercial manufacturing.
  2. Generic Product Development and Manufacturing Partnerships: Customized deal structures ranging from Free-For-Service to Profit Sharing collaborations for Generic Product development and manufacturing partnerships. Focus on Therapeutically Equivalent ANDA-based products, OTC and other products on a case-by-case basis.
  3. Finished Solid Dosage Form Products: Manufacturing and sale of finished solid dosage forms including Tablets (Ranitidine, Levetiracetam, Tadalafil), Capsules, and Pellets (Omeprazole, Itraconazole, Esomeprazole, Duloxetine) across various therapeutic segments.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels4 records

VKT Pharma product offering

Product offering

Core offering

VKT Pharma is a vertically integrated pharmaceutical company that manufactures and supplies tablets, capsules, and ready-to-fill immediate or modified-release pellets for generic drug formulations. The company offers Contract Research and Manufacturing Services (CRAMS), Novel Drug Delivery Systems (NDDS), and end-to-end pharmaceutical solutions spanning product development, formulation development, analytical development, regulatory affairs, and commercial manufacturing across a wide range of therapeutic segments including anti-ulcer, anti-fungal, anti-depressant, anti-retroviral, anti-epileptic, and BPH treatments.

Product overview

VKT Pharma is a quality-driven pharmaceutical company with vertically integrated operations spanning the entire pharmaceutical value chain from product development to delivery. The company specializes in Research & Development, Manufacturing and Marketing of Solid Dosage Forms with focus on Tablets, Capsules & Ready to Fill Immediate or Modified release Pellets. The core product portfolio includes Commercial Pellets (Omeprazole, Itraconazole, Esomeprazole, Duloxetine), Finished Formulations (Ranitidine Tablets, Levetiracetam Tablets, Tadalafil Tablets), and an extensive development pipeline including anti-retroviral products. The company offers Contract Research and Manufacturing Services (CRAMS) and Novel Drug Delivery Systems (NDDS) alongside formulation development services. Manufacturing operations are conducted across dedicated blocks: Block A (OSD - 4.4Bn tablets/capsules capacity), Block B (Pellets - 360 MT/annum capacity), and Block C (Central Warehouse).

Differentiator

Problem solved

Functional benefit

Products and services

  • Commercial Pellets (Omeprazole, Itraconazole, Esomeprazole, Duloxetine) Commercially available pharmaceutical pellets including Omeprazole Pellets (8.5% & 9.0%), Itraconazole Pellets (20%, 22% & 32.25%), Esomeprazole Pellets (8.5%), and Duloxetine Pellets (17%) for anti-ulcer, anti-fungal, and anti-depressant therapeutic segments.
  • Ranitidine Tablets (150mg, 300mg) Ranitidine Tablets in 150mg and 300mg strengths for anti-ulcer treatment, recently approved by US FDA after reformulation addressing NDMA impurity concerns.
  • Levetiracetam Tablets (250mg, 500mg, 750mg, 1000mg) Levetiracetam Tablets in 250mg, 500mg, 750mg, and 1000mg strengths for anti-epileptic treatment.
  • Tadalafil Tablets (2.5mg, 5mg, 10mg, 20mg) Tadalafil Tablets in 2.5mg, 5mg, 10mg, and 20mg strengths for erectile dysfunction (ED) treatment.
  • Formulation Development Services Comprehensive formulation development for tablets (immediate release, delayed release, extended release, sustained release, bi-layered, coated, MUPs, fixed dose combinations, gastro-retentive systems, sublingual), capsules, pellets, liquid orals, and powders/granules.
  • Contract Research and Manufacturing Services (CRAMS) End-to-end pharmaceutical solutions from research to delivery of finished products, including 505(b)(2) and new drug product development, platform technology analysis, and regulatory support.

Quantifiable outcome

  • First-to-file status and 180 days exclusivity achieved for number of Para IV products
  • +1 more outcomes

Companies that use VKT Pharma

Customer profile

Named customers1 record

Segments3 records

Ideal customer profiles2 records

VKT Pharma technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature8 records

VKT Pharma partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • SMS Pharmaceuticals LtdcoreStrategic or Co-development PartnerSMS Pharmaceuticals Ltd is the parent/associate company of VKT Pharma. VKT Pharma operates as an associate firm under the SMS Group. The relationship provides strategic alignment and shared resources within the Indian pharmaceutical industry. SMS Pharma's stock performance (18% gain following VKT's US FDA approval) demonstrates the strategic importance of this partnership.

Scale indicators6 records

Recent moves8 records

Expansion highlights5 records

VKT Pharma competitors and assessment

Company assessment

Broad incumbents

  • Hetero Labs: Indian pharmaceutical company with strong ARV franchise and formulation manufacturing capabilities; comparable through its presence in VKT's anti-retroviral development pipeline space and its generic solid-dosage manufacturing for global markets.
  • Divis Laboratories: Indian API and intermediates manufacturer with growing formulation services and strong regulatory credentials; competes in the CDMO and complex generics space that VKT targets, particularly for global pharma partners.
  • Aurobindo Pharma: Large Indian pharmaceutical company with substantial generic finished dosage, API, and ARV franchises plus US FDA-approved facilities; competes for similar CRAMS and generic formulation contracts although at a much larger scale.
  • Dr. Reddy's Laboratories: Major Indian generics and CDMO player with US FDA-inspected facilities offering formulation development, contract manufacturing, and complex generics including modified-release products, overlapping VKT's target market.
  • Piramal Pharma Solutions: Global CDMO with development and manufacturing capabilities across sterile injectables, oral solids, and APIs; directly comparable in CRAMS service offering but operates at much larger scale across multiple geographies.

Emerging players

  • Laurus Labs: Indian CDMO with API, formulation, and CRO services targeting global pharma; comparable to VKT as a mid-sized Indian player pursuing regulated-market manufacturing and complex formulation services.

Direct peers

  • Granules India: Indian pharmaceutical manufacturer focused on finished dosages, API, and intermediates with strong pellet and tablet capabilities serving global generic markets; highly comparable to VKT in product mix (tablets, capsules, pellets) and CRAMS-style services targeting regulated markets.
  • Natco Pharma: Indian pharmaceutical company specializing in complex generics and Para IV filings for the US market, with strong modified-release and oncology product development; closely comparable to VKT's complex-generics, Para IV, and first-to-file focus.
  • SMS Pharmaceuticals: Parent/associate company of VKT Pharma and a leading Indian API manufacturer with growing formulation interests; shares leadership, strategic alignment, and Hyderabad base, making it the most direct comparability benchmark for VKT's operations.
  • ScieGen Pharmaceuticals: US-based but India-manufactured generic pharmaceuticals producer focused on solid oral dosage forms with US FDA-approved facilities; similarly positioned as a mid-tier CDMO/generic player competing for outsourced manufacturing partnerships and complex generic approvals.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

VKT Pharma social profiles

Digital presence

VKT Pharma compliance and trust

Trust signal

Compliance4 records

VKT Pharma financial estimates

Financial estimate

Revenue estimate

Valuation estimate

VKT Pharma leadership team

Management profile

Number of profiles

Profiles2 records

VKT Pharma funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

VKT Pharma M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about VKT Pharma

What does VKT Pharma do?

VKT Pharma is a vertically integrated pharmaceutical company that manufactures and supplies tablets, capsules, and ready-to-fill immediate or modified-release pellets for generic drug formulations. The company offers Contract Research and Manufacturing Services (CRAMS), Novel Drug Delivery Systems (NDDS), and end-to-end pharmaceutical solutions spanning product development, formulation development, analytical development, regulatory affairs, and commercial manufacturing across a wide range of therapeutic segments including anti-ulcer, anti-fungal, anti-depressant, anti-retroviral, anti-epileptic, and BPH treatments.

Is VKT Pharma a public or private company?

VKT Pharma is a private company. It is classified as corporate owned and is currently operating.

When was VKT Pharma founded?

VKT Pharma was founded in 2009. It employs 101 to 250 people.

Where is VKT Pharma based?

VKT Pharma is headquartered in Hyderabad, India, in the Asia region.

How does VKT Pharma make money?

Three revenue lines are on record. Contract Research and Manufacturing Services (CRAMS) is the primary driver. The others are generic Product Development and Manufacturing Partnerships and finished Solid Dosage Form Products.

Who are VKT Pharma's main competitors?

Broad incumbents on record are Hetero Labs, Divis Laboratories, Aurobindo Pharma, Dr. Reddy's Laboratories and Piramal Pharma Solutions. Laurus Labs is listed as an emerging player. Direct peers are Granules India, Natco Pharma, SMS Pharmaceuticals and ScieGen Pharmaceuticals.

Does VKT Pharma have an API?

No public API is recorded for VKT Pharma.

What industry is VKT Pharma in?

VKT Pharma's product category is Pharmaceutical Contract Manufacturing. Its primary akta.pro industry code is HLAIABAH, Generic Finished Dosage Form (FDF) Manufacturing, with a secondary code of HLAGAHAL, GMP Scale-Up, Tech Transfer & Process Validation (PPQ). Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals